POLAREAN
PharmaPOLAREAN is a pharmaceutical company focused on Respiratory. Key products include XENOVIEW.
FDA Novel Drug Designations
(2022)See 1 novel approval →
POLAREAN's Key Drugs
POLAREAN's core commercial portfolio centers on XENOVIEW, spanning Respiratory — its most strategically important drugs approved in the last 15 years.
POLAREAN's Recent FDA Approvals
New NDA/BLA approvals for POLAREAN over the last two years — novel drugs only, excluding generics and label supplements.
POLAREAN's Therapeutic Areas
POLAREAN's approved drugs and pipeline span 1 therapeutic area, led by Respiratory, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
POLAREAN's Top Competitors
POLAREAN's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and GSK. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
POLAREAN Pipeline Snapshot
POLAREAN has 2 active clinical programs from ClinicalTrials.gov — 2 Phase 3, 0 Phase 2 and 0 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • XENOVIEW leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Respiratory pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2022-12-23
- Latest
- 2025-05-30
- Applications
- 1